B. Christopher Kim
Direktor/Vorstandsmitglied bei BRIDGE BIOTHERAPEUTICS, INC.
Profil
Chris is a life sciences investor, entrepreneur and operations executive with deep experience in venture capital and the pharmaceutical industry.
He currently serves as the managing partner of Novatio.
He also serves as the managing partner of the Korea-Seoul Life Science Fund (www.kslsfund.com), which he co-founded while at Oxford Bioscience Partners.
He is considered a trailblazer in cross-Pacific venture capital investing.
Previously, Chris was Associate Director and Head of Operations for the Global BioMarker Development group at the Novartis Institutes for BioMedical Research where he managed NIBR’s biomarker portfolio for the general medicine division.
He held an additional role in corporate development while at Novartis.
He also worked at Alkermes as a scientific researcher and at IBM as an associate.
Chris is active as either a board member or advisor for a number of emerging biotech companies located in Boston, Korea and Israel.
Chris holds an MBA from Carnegie Mellon University, a PhD in Biomedical Sciences from the University of Texas Health Science Center and the MD Anderson Cancer Center with a focus on developmental biology, and a dual bachelor's degree in economics and biology from the University of California at Irvine
Aktive Positionen von B. Christopher Kim
| Unternehmen | Position | Beginn |
|---|---|---|
| BRIDGE BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.09.2016 |
Novatio Ventures
 Novatio Ventures Investment ManagersFinance Novatio Ventures (Novatio Ventures) is a venture capital firm founded in 2015 by Peng Fu. The firm is headquartered in Toronto, Canada. | Private Equity Investor | 01.01.2015 |
The Korea Seoul Life Science Fund
 The Korea Seoul Life Science Fund Financial ConglomeratesFinance The Korea Seoul Life Science Fund provides investment services. | Gründer | 01.01.2011 |
Ehemalige bekannte Positionen von B. Christopher Kim
| Unternehmen | Position | Ende |
|---|---|---|
| CHONG KUN DANG PHARMACEUTICAL CORP. | Berater | 01.06.2021 |
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Direktor/Vorstandsmitglied | 01.06.2021 |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Private Equity Investor | 01.12.2017 |
Ausbildung von B. Christopher Kim
| Carnegie Mellon University | Masters Business Admin |
| University of Texas Health Center | Doctorate Degree |
| The Institute for Money, Technology & Financial Inclusion | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRIDGE BIOTHERAPEUTICS, INC. | Health Technology |
| CHONG KUN DANG PHARMACEUTICAL CORP. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Novatio Ventures
Novatio Ventures Investment ManagersFinance Novatio Ventures (Novatio Ventures) is a venture capital firm founded in 2015 by Peng Fu. The firm is headquartered in Toronto, Canada. | Finance |
The Korea Seoul Life Science Fund
The Korea Seoul Life Science Fund Financial ConglomeratesFinance The Korea Seoul Life Science Fund provides investment services. | Finance |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Technology Services |